Efficacy analysis of a novel compound in a humanized mouse model for psoriasis and development of the humanized mouse model
Completed
- Conditions
- flaking diseasePsoriasis1000381610014982
- Registration Number
- NL-OMON38904
- Lead Sponsor
- TNO
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 33
Inclusion Criteria
Psoriasis patients: Adults (m/f) with a mild to moderate form of psoriasis vulgaris (PASI score of maximal 18 and minimum BSA of 3%). Patients are allowed to use local corticosteroids or ointments to prevent dry skin (see Appendix 2).
Exclusion Criteria
These patients have not received light therapy or another form of systemic treatment (methotrexate, cyclosporin A, anti-TNF treatments). Gender or age of the adults are not exclusion criteria (see Appendix 2).
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Effect on the psoriatic process is tested by histology and immuno-histochemical<br /><br>techniques in the transplanted biopsies. Main read-out is epidermal thickness.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Secretion of inflamatory mediators by celsl from patients.<br /><br>Markers on cultured cells from psoriasis patients.<br /><br>Differentiation and proliferation markers in skin.</p><br>